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Abstract
Background: The usual surgical treatment of refractory sciatica caused by lumbar disc herniation, is open
discectomy. Minimally invasive procedures, including percutaneous therapies under local anesthesia, are
increasingly gaining attention. One of these treatments is Percutaneous Laser Disc Decompression (PLDD). This
treatment can be carried out in an outpatient setting and swift recovery and return to daily routine are suggested.
Thus far, no randomized trial into cost-effectiveness of PLDD versus standard surgical procedure has been
performed. We present the design of a randomized controlled trial, studying the cost-effectiveness of PLDD
versus conventional open discectomy in patients with sciatica from lumbar disc herniation.
Methods/design: The study is a randomized prospective multi-center trial, in which two treatment strategies
are compared in a parallel group design. Patients (age 18–70 years) visiting the neurosurgery department of the
participating hospitals, are considered for inclusion in the trial when sciatica due to lumbar disc herniation has
lasted more than 8 weeks. Patients with disc herniation smaller than 1/3 of the spinal canal diameter, without
concomitant lateral recess stenosis or sequestration, are eligible for participation, and are randomized into one
of two treatment arms; either Percutaneous Laser Disc Decompression or conventional discectomy. The
functional outcome of the patient, as assessed by the Roland Disability Questionnaire for Sciatica at 8 weeks and
1 year after treatment, is the primary outcome measure. The secondary outcome parameters are recovery as
perceived by the patient, leg and back pain, incidence of re-intervention, complications, quality of life, medical
consumption, absence of work and secondary costs.
Discussion: Open discectomy is still considered to be the golden standard in the surgical treatment of lumbar
disc herniation. Whether Percutaneous Laser Disc Decompression has at least as much efficacy as the standard
surgical procedure, and is more cost-effective, will be determined by this trial.
Trial registration: Current Controlled Trials ISRCTN25884790.
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In the majority of patients, experiencing their first episode
of sciatica due to lumbar disc herniation, the symptoms
recede to a non-disabling level within a period of six
weeks [1]. The historical mainstay in the treatment of sci-
atica in patients in which the complaints are refractory to
conservative treatment is discectomy [2]. This treatment is
aimed at the removal of the herniated disc fragment that
is the cause of nerve root compression. Another way of
decompressing the nerve root is by inducing a negative
pressure in the intervertebral disc by removal of tissue.
Several percutaneous techniques are based on this princi-
ple [3]. Percutaneous Laser Disc Decompression (PLDD),
being one of these techniques, is a modality in which laser
energy is delivered to the nucleus pulposus by means of a
fiber [4]. This fiber is inserted through a thin needle via a
posterolateral percutaneous approach under local
anesthesia. The absorption of the applied laser energy
leads to vaporization of the water content of the nucleus
pulposus in combination with a change in protein struc-
ture thereof. The subsequent volume reduction causes a
disproportionate decrease in intradiscal pressure and
relieves the nerve root. The first clinical percutaneous laser
disc decompression was performed in Europe by Choy
and Ascher in 1986 [5]. The U.S. Food and Drug Admin-
istration approved PLDD for use in the USA in 1991.
PLDD is an attractive treatment because of the minimally
invasive nature and therefore the assumed decrease in risk
of structural damage to the muscles, bone, ligaments and
nerves. Furthermore, the patients are expected to have less
back pain, shorter hospitalization and a shorter reconva-
lescence period than with conventional surgery. The
actual recovery of the sciatica however, might take more
time than after conventional surgery, although immediate
resolution of the symptoms does occur.
Although several cohort studies have been published, and
FDA approval was given, to date no randomized trial has
been performed comparing PLDD with conventional sur-
gical procedures. The cohort studies showed the safety
and potential benefits of PLDD. No evidence regarding
the efficacy and cost-effectiveness of PLDD, compared to
conventional surgery, is available to date [6].
Currently, there is broad consensus that conventional sur-
gery is the gold standard for surgical intervention for sci-
atica; therefore PLDD has to be compared to conventional
surgery in order to assess the cost-effectiveness. The result
will be a trade-off between the expected more swift recov-
ery of the patients in the 'gold standard' group versus the
minimally invasive nature, lower costs and patient com-
fort of the PLDD treatment, which might take a slightly
longer period to full recovery. Several subgroups will be
identified in a post-hoc analysis, using pre-defined poten-
tial risk factors, which might especially benefit from the
PLDD treatment. It is hypothesized that the potential
result, immediately after treatment, is non-inferior at
longer follow-up. In this study the patients will therefore
be assessed for primary endpoints at 8 weeks and 1-year
follow up and additional endpoints up to 2 years.
Methods/Design
We designed a randomized prospective open trial aimed
at showing non-inferiority of PLDD to the surgical treat-
ment of lumbar disc herniation. Both treatments are com-
pared in a parallel group design with at least a 2-year
follow-up. The Roland Disability Questionnaire for Sciat-
ica will be used as the primary outcome measure to deter-
mine the power of the study. A multi-center approach is
used to assure a sufficient recruitment of participating
patients. In this case 2 academic hospitals and 6 teaching
hospitals will recruit patients. We received full approval of
the ethics committees in all participating hospitals.
Patients
All patients between 18 and 70 years of age with sciatica
since 6–8 weeks, presenting at the neurosurgical depart-
ment, are eligible for inclusion in the trial. A disc hernia-
tion at the appropriate level will have to be shown by MRI.
The herniated fragment has to be smaller than 1/3 of the
spinal canal (figure 1). The remainder of the patients (i.e.
those with a herniated fragment > 1/3 of the spinal canal)
Measuring the disk herniationFigure 1
Measuring the disk herniation. The size of the herniated 
disc is measured in relation to the spinal canal diameter at 
disc level. The size should not exceed one third of the total 
spinal canal diameter.Page 2 of 7
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Micro Endoscopic Discectomy (MED) versus conven-
tional surgery [7]. Patients' history and standard neuro-
logical examination will be documented by the
neurosurgeon, who subsequently decides on the eligibil-
ity of the patient for the trial, based on Table 1, and
explains the trial to the patient. If the patient is willing to
participate, an appointment is made with one of the
research nurses. This visit is planned at least 2 days later to
give the patient ample time to decide on entering the
study. After informed consent the research nurse records
the baseline variables, questionnaires and outcome meas-
ures.
Randomization procedure
Patients will be randomly allocated to PLDD or conven-
tional surgery. This randomization will take place during
the outpatient visit with the research nurse following the
informed consent procedure, but after completion of the
baseline assessments. A randomization list is prepared for
every participating hospital/nurse combination. Variable
sized blocks of random numbers are formed to ensure
equal distribution of the randomization treatments over
hospitals and research nurses. The data manager at the
department of Biostatistics, who is not involved in the
selection and allocation of patients, will prepare coded,
sealed envelopes containing the treatment allocation. The
patient will open the envelope in the presence of the
research nurse.
Intervention
Patients will be allocated to either discectomy (A) or
PLDD (B), which will take place within 4 weeks after
inclusion.
(A) Open discectomy
Depending on the surgeon and patient's preference, sur-
gery will be performed under general or spinal anesthesia.
The patients will be positioned prone and the affected disc
level is verified with fluoroscopy. A small midline incision
(2–3 cm) will be made and the paravertebral muscles will
be dissected unilaterally. Laminotomy will be performed
when deemed necessary. In order to decompress the nerve
root, the herniated disc will be removed as much as possi-
ble through a unilateral transflaval approach. The wound
will be closed in layers with a suction drain when neces-
sary. Patients will be operated with loupe magnification
or microscope depending on the surgeon's preference.
The participating surgeons have large experience in the
technique. A standardized case record form (CRF) will
register the surgeon's findings and will be send to the data
center. Patients will be admitted to hospital for 2–7 days
depending on the usual care.
(B) Percutaneous Laser Disc Decompression
The patient will be instructed to take a prone position on
the table of the CT-scan. After placing sterile drapes the
level of treatment is identified by a scan. The needle entry
point is anesthetized by local lidocaine injection no
deeper than the facet joint. Subsequently the 18G needle
is placed centrally in the nucleus pulposus, and parallel to
the endplates by means of a posterolateral approach.
Through the needle, a glass fiber is placed in the disc, ena-
bling the application of laser energy (980 nm, 7 W, 0,6 s
pulses, interval 1 second). After a total energy of 1500 J is
delivered (2000 J for level L4-5), the procedure is finished.
A control CT scan is performed to assess gas formation in
the disc space. After the treatment the patient is allowed to
drink tea or coffee and is observed for 15 minutes before
he/she can return home.
Both treatment strategies will be followed by active mobi-
lization in the post-operative period. Patients in the sur-
gery group will be discharged as soon as possible. Early
resumption of daily activities and work will be stimulated
in both study groups.
Table 1: Selection criteria for patient eligibility
Inclusion:
*Age 18–70 years
*Persistent Radicular pain lasting more than 6–8 weeks
*Operation indication
*Disc herniation confirmed at MRI
*Unilateral disc herniation smaller or equal to 1/3 of the spinal canal
*Informed consent
Exclusion:
*Previous surgery at the same disc level
*Cauda equina Syndrome
*Spondylolytic or degenerative spondylolisthesis
*Central spinal canal stenosis
*Pregnancy
*Severe somatic or psychiatric illness
*Planned (e)migration to another country in the year after the inclusion
*Inadequate verbal or writing skills in Dutch languagePage 3 of 7
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At baseline we will register demographics, hobbies, sports,
work status, smoking status, back pain history, family his-
tory of sciatica, co-morbidity, patients satisfaction at
work, weight and length. The treatment preference of both
patient and the including surgeon will be noted on a 5-
point scale ranging from "strong preference for conven-
tional open discectomy" to "strong preference for PLDD".
We will also register the expected recovery at 8 weeks after
randomization as expected by both surgeon and patient.
The baseline questionnaires for the primary endpoints are
also collected.
Outcome assessment
The assessment of outcome will use several validated out-
come parameters as described below. Patients will
undergo neurological examination by the research nurse
at 4, 8, 26, and 52 weeks (Table 2). Questionnaires will
also be filled out at these follow-up moments. At 1, 2, 6,
12, 38, 78, and 104 weeks the questionnaires will be filled
out by the patient at home, and subsequently send to the
data collection center by regular mail. Outpatient control
by the neurosurgeon takes place at 8 weeks and thereafter
if deemed necessary. The follow-up moments of data col-
lection and outcome measures are listed in Table 3.
Our goal is to show clinical equivalence between the two
treatment strategies at various time points. The 1-year fol-
low-up will be the most important clinical landmark. The
cost-effectiveness analysis will therefore be performed
using the clinical and economical parameters at 1 year.
Primary outcome measure
Roland Disability Questionnaire for Sciatica (RDQ) is an
illness-specific 23-item functional assessment question-
naire that is frequently used for low back pain and sciatica
[8-11]. The score, ranging from 0 to 23, reflect a sum of
items experienced by the patient. The higher the score the
more disabling the sciatica is perceived. The score will be
analyzed as a continuous outcome variable. For descrip-
tive purposes, "Recovery" (at the individual level) is
defined by a difference of at least 11 points from baseline.
A difference of 4 points for the averages between the two
randomization arms is considered the maximum for
"equivalence" of the two treatment modalities. The RDQ
has established validity, reliability and responsiveness to
change [12]. This outcome measure is used to determine
the power of the study.
Other parameters that will be used from primary end-
point analyses are:
1) Perceived recovery
This is a 7-point Likert scale measuring the perceived
recovery, varying from 'complete recovery' to 'worse than
ever'. This outcome scale has been used in previous stud-
ies and is regarded valid and responsive to change [13].
We will also score a job- and hobby specific Likert in
which the patient will be asked to rank their 5 most
important functional disabilities which will be used in
their own evaluation overall and in separate items.
2) Visual Analog Scale (VAS) of leg pain
The experienced pain intensity in the leg will be assessed
at fixed intervals on a visual analog scale. The scale will
measure 100 mm varying from 0 mm 'no pain' to 100 mm
'the worst pain imaginable'. The VAS has shown reliabil-
ity, validity and responsiveness [14].
3) Visual Analog Scale (VAS) of back pain
Many of the patients have, in addition to their radicular
pain, back pain as well. The back pain will be assessed by
means of a VAS
Additional (secondary) outcome measures
1) McGill pain questionnaire
Perceived pain will be measured by using the Dutch ver-
sion of the validated McGill Questionnaire [15].
2) Short-form 36 (SF 36)
The RAND-SF 36 is a generic health status questionnaire
that consists of 36 items on physical and social status of
the patient subdivided in 8 domains. These are physical
functioning, physical restrictions, emotional restrictions,
social functioning, somatic pain, general mental health,
and vitality and general health perception. The questions
add up to a score of 0 (worst health) to 100 (ideal health).
The SF 36 has been validated for surgical studies on low
back pain pathology [16-18].
3) Sciatica Frequency and Bothersome Index (SFBI)
This scale, ranging from 0 to 6, can asses frequency (0 =
never, 6 = always) and bothersome (0 = not at all, 6 =
extreme bothersome) of back and leg pain. The sum of the
questions ranges from 0 to 24 [8,19].
Table 2: Neurological examination
*Straight leg raising test (Lasègue)
*Crossed straight leg raising test (Crossed Lasègue)
*Sensory loss
*Dermatome anesthesia
*Muscle weakness
*Knee tendon reflex difference
*Ankle tendon reflex difference
*Finger-ground distance in centimeter
Lasègue's sign is defined positive if the patient experiences a typically 
dermatomal area of pain reproduction and pelvic muscle resistance 
below a unilateral 60 degrees angle provocative straight leg raising. 
'Crossed positive' if the same experience was noted with straight 
raising of the contralateral leg below 90 degrees.Page 4 of 7
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The Prolo scale measures the evaluation of the surgeon
and research nurse of the patient's functional and eco-
nomic status. It is a current scale in outcome studies of
lumbar spinal surgery [20,21].
5) Costs
Direct medical costs of hospital admission and surgery as
well as PLDD related costs will be based on an integral
cost-analysis in the participating hospitals. From this
analysis, the constant costs per treatment and the variable
costs will be estimated. Other medical costs (physiother-
apy, general practitioner, nursing care, medication and
medical specialists) will be registered in a diary. Non-
medical costs (time, travel expenses, domestic help) will
also be included in the diary. The research nurse will go
through the diary with the patient on every follow-up
moment throughout the first 2 years. To estimate the indi-
rect costs the patient will register absenteeism. The
research nurse will register the work situation, work effi-
ciency and gross income on the follow-up moments.
Absenteeism will be valued to the friction-cost method.
6) Incidence of re-operations
The incidence of re-operation will be used as an outcome
measure.
7) Complications
Complications will be registered systematically. This
includes wound infection, deep venous thrombosis, urine
tract infection, hematoma and progressive neurological
deficit. The surgeon and research nurse will register the
complications at the follow-up moments.
Sample size
The study is designed as an equivalence study with asym-
metric boundaries, leading to a non-inferiority design. A
difference of 4 on the Roland Disability Questionnaire
has been recognized as the minimum clinically important
difference. The power calculation is performed under the
alternative hypothesis of a difference of 1 point on the
Roland scale. By using this value 4 as the upper limit of
the equivalence interval, with α-level of 0.05, a power of
0.90 and a SD of 5, the required sample size was 98 (49
per treatment arm). To adjust for an 8% loss to follow up,
Table 3: Data collection and outcome measures
RN RN RN RN RN
Time in weeks X 0 2 4 6 8 12 26 38 52 78 104
Treatment preference patient v v v v
Neurological examination v v v v v
Likert v v v v v v v v v v v v
Prolo v v v v v
Severity of complaints (VAS) v v v v v v v v v v v v
Functional status (Roland DQS) v v v v v v v v v v v
McGill v v v
Health status (Rand/SF 36) v v v v v v v
EuroQol v v v v v v v v v v v v
SFB Index v v v V v
Costs (diary) v v v v v V v v
Surgery/PLDD v
Complications v v v v v
"RN" marks the scheduled meetings with the Research Nurse.Page 5 of 7
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based on a comparison of average at single points in time.
By using a repeated measurements analysis of variance,
the power of the study over the entire follow-up period
will be substantially higher (or equivalently, the average
difference between the treatments can be established
more accurately).
Statistical analysis
Baseline comparability between the two treatment groups
will be evaluated with respect to disease characteristics,
demographics and baseline values of self-report measures.
Chi-square or Student t-test, as appropriate, will be used
for these comparisons, although decisions to adjust for
one or more of the base line characteristics in the actual
analyses will not be based on statistical significance but
on the relevance of the confounding effects in case of
imbalance occurring in spite of the balanced randomiza-
tion procedure. The analysis will be performed in accord-
ance with the "intent-to-treat principle", analyzing all
patients within their randomization groups, regardless of
whether they completed the allocated treatment. Intent-
to-treat analysis often leads to smaller observed treatment
differences, thereby increasing the risk of type I error
(claiming there is non-inferiority/equivalence, when there
is not). Therefore, a per-protocol analysis is also carried
out and differences in results will be described.
The analysis will consist of assessment of differences in
outcome measurements between both groups and differ-
ences in time to recovery. It will take into account the
stratification factors (center; research nurse) as covariates
in accordance with ICH E9. Other base line covariates,
measured before randomization, may be incorporated
into the analysis models to increase power and to remove
any residual confounding. An assessment of interaction
between the treatment on the one hand and the stratifica-
tion variables, or. main baseline covariates, will be con-
sidered as a mandatory part of the primary analysis and a
proper interpretation of efficacy. The "difference" between
the two treatment arms, the treatment effect (on the
appropriate scale) will be reported both as an overall
(adjusted) value and – in the case of significant effect
modification – in terms of its dependence on the catego-
ries or values of the effect modifiers. A significant interac-
tion between the stratifying factors or main baseline
covariates will be considered as part of a proper modeling
strategy and will not imply correction for repeated signif-
icance testing. After fitting the proper model, inference on
the treatment effect will be based on the smallest fitting
model that allows estimation of the treatment effect.
When analyzing the primary outcome measure, Roland,
the primary analysis will be a repeated measurement anal-
ysis of variance, hence estimating the original measure-
ments. As a secondary analysis of this primary outcome
variable, we will define "Roland-recovery" as a change of
at least 11 points between baseline and any point in time
post randomization. This dichotomization of the Roland
score will be used as the outcome variable in a Cox regres-
sion analysis modeling time till recovery. The multivariate
analysis will be performed along the same principles for
variable selection and model building as outlined above.
A subgroup analysis is preplanned and will be performed
to assess differences in treatment effect in subgroups of
patients. (Table 4)
Data will be stored via the internet-based secure data man-
agement system (ProMISe) of the department of Medical
Statistics and Bioinformatics. The analysis will be carried
out using SPSS.
Discussion
With this publication we introduce the design of the first
randomized controlled trial on the cost-effectiveness of
PLDD versus conventional surgical discotomy for sciatica
in lumbar disc herniation. This randomized controlled
trial is a prospective trial comparing the effects of the tech-
niques as well as the economical costs. The aim is to inves-
tigate whether both treatment modalities are equivalent
in their clinical effect and to study their cost-effectiveness.
The inclusion is complete as off the end of 2007 with fol-
low-up measurements going on until at least the end of
2009.
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